Trials / Recruiting
RecruitingNCT07450144
A Large Language Model-based Chatbot for Alcohol Reduction in Patients With Metabolic Alcohol-Related Liver Disease
A Large Language Model-based Chatbot for Alcohol Reduction Counseling in MetALD Patients: A Pilot Randomized Controlled Trial
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- The University of Hong Kong · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of LLM-based chatbot for reducing alcohol use among patients with metabolic alcohol-related liver disease. Specific objectives include: 1. To assess how many MetALD patients accept the invitation to participate in the trial 2. To assess the retention rate of the participants through 3 and 6 months after treatment initiation 3. To assess the acceptability of the LLM-based chatbot in terms of participants' compliance and usability rating 4. To estimate the intervention effect on alcohol reduction 5. To explore the participants' perception and experiences in the chatbot
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | LLM-based chatbot | Over the three months following randomisation, an LLM-based chatbot will interact with each participant individually to deliver four personalized sessions of alcohol reduction information and advice, and participants will also be allowed to contact the chatbot at any time. |
| BEHAVIORAL | Telephone counseling | Over the three months following randomisation, a trained counsellor will conduct four individual daytime telephone sessions with each participant to provide personalised information and advice on reducing alcohol consumption. |
| BEHAVIORAL | Alcohol Brief Intervention | Brief counselling (5 to 10 mins) to reduce drinking and a self-help booklet |
Timeline
- Start date
- 2026-03-18
- Primary completion
- 2027-05-22
- Completion
- 2027-07-22
- First posted
- 2026-03-04
- Last updated
- 2026-03-23
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT07450144. Inclusion in this directory is not an endorsement.